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Pharmacokinetics of trazodone and its major
metabolite m-chlorophenylpiperazine in plasma
and brain of rats
C. Lindsay DeVane, David W. Boulton, Lisa F. Miller and Ronald L. Miller
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina
Abstract
Sprague–Dawley rats were used as models for single trazodone administration (males), continuous
adminstration and dose proportionality experiments (males, females, pregnant females). Plasma and brain tissue
were analysed for trazodone and its active metabolite, m-chlorophenylpiperazine (m-CPP). Fetal exposure to
trazodone and m-CPP was assessed and differences in their steady-state plasma concentration were sought
between adult males and females. Both trazodone and m-CPP rapidly appeared in plasma and brain tissue
following a single intraperitoneal trazodone dose with brain concentrations exceeding those in plasma.
Plasma concentrations of m-CPP were lower than those of trazodone but exceeded them in brain tissue.
Chronic administration using osmotic mini-pumps revealed a significant linear relationship between trazodone
concentration in plasma and brain at steady-state (r¯ 0±96, p! 0±0001). No simple relationship was found
between plasma and brain tissue concentration for m-CPP. In contrast to observations following single
trazodone administration, m-CPP concentrations at steady-state were lower than trazodone concentrations in
brain tissue, suggesting a lack of stationarity in the disposition of trazodone over time. No significant
differences in plasma or brain tissue drug concentrations relative to administered trazodone dose were
observed between male and female rats, nor between pregnant and non-pregnant females. Trazodone and m-
CPP were both detected in fetal and placental tissues, with placenta having the highest concentrations. The
data suggest that neuropharmacological studies of trazodone could yield different results depending upon the
route and schedule of drug administration. Maternally administered trazodone, like many other antidepressants,
is distributed to fetal tissues in rodents, reaffirming the need for caution in treating pregnant women with
psychoactive drugs.
Received 23 September 1998 ; Reviewed 9 November 1998 ; Revised 28 November 1998 ; Accepted 6 December 1998
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Introduction
Trazodone hydrochloride is a triazolopyridine derivative
possessing antidepressant and possibly antianxiety ac-
tivity. It differs from other major classes of antidepressant
agents in several respects, including structure, pharma-
cology, and toxicity (Brogden et al., 1981). Trazodone
was the first of the ‘ atypical ’ antidepressants to find
widespread use in the United States and Europe. Major
depression is the principal indication for the clinical use of
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trazodone. It is commonly used in combination with
selective serotonin reuptake inhibitors to provide night-
time sedation.
In defining the preclinical pharmacology of this drug,
Maj et al. (1979) found single trazodone administration to
rats produced the pharmacological effects of a serotonin
antagonist at low doses, while at higher doses, it
possessed direct receptor agonist properties. Subsequent
studies suggested that the latter effect was due to the
actions of 1-m-chlorophenylpiperazine (m-CPP) rather
than a dual action attributable to trazodone alone (Cervo
et al., 1981 ; Melzacka et al., 1979). This metabolite is the
result of hydrolysis and oxidation occurring on the side-
chain of the parent compound (Caccia et al., 1981a, 1982 ;
Melzacka et al., 1979). It is also a minor metabolite of the
antidepressants etoperidone, mepiprazole and nefazodone
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(Barbhaiya et al., 1996 ; Fong et al., 1982a). The formation
of m-CPP from trazodone in humans appears to be
mediated by cytochrome P
%&!
(CYP) 3A4 (Rotzinger et al.,
1998) which in turn can be further biotransformed to
p-hydroxy-m-CPP by CYP2D6 (Barbhaiya et al., 1996).
There is little information on which specific CYP isoforms
are responsible for m-CPP formation in the rat.
Basic pharmacokinetic studies of trazodone have been
carried out in normal human volunteers using single doses
(Ankier et al., 1981 ; Bayer et al., 1983 ; Caccia et al., 1982 ;
Greenblatt et al., 1987) or following multiple doses in
psychiatric patients (Allroy et al., 1978 ; Ishida et al., 1995 ;
Lawlor et al., 1997 ; Nilsen et al., 1993). Our knowledge of
the disposition of trazodone and particularly that of its
active metabolite in brain tissue compared to plasma is
limited. However, some animal studies have been carried
out where, following oral administration of trazodone,
m-CPP appeared in the rat brain at a concentration
comparable to that found following pharmacologically
and biochemically effective doses of m-CPP (Caccia et al.,
1981b ; Cervo et al., 1981 ; Smith and Suckow, 1985). In
addition, the concentration both of the parent drug and
metabolite in the brain was several times greater than that
measured in plasma. The higher concentrations of trazo-
done in the brain compared to plasma probably also exist
in humans as post-mortem analysis in overdose cases
found trazodone brain :plasma ratios of 3±4 and 1±4
(Martin and Pounder, 1992). The data, together with the
observation that the metabolite reaches measurable
plasma concentrations in humans receiving trazodone
(Ishida et al., 1995 ; Lawlor et al., 1997), suggest that m-
CPP contributes directly to or interacts with trazodone in
producing antidepressant, antianxiety or adverse effects.
We sought to further understand the pharmacokinetics
of trazodone and m-CPP by following the concentrations
in plasma and brain of rats after single and continuous
trazodone administration. In addition, we also investi-
gated whether there were any gender differences in
trazodone or m-CPP disposition and assessed their
placental transfer and distribution in the rat fetus.
Methods
Single dose administration
All animal experiments were approved by the local
Institutional Animal Care and Usage Committee. Male
Sprague–Dawley rats weighing between 125 and 150 g
were used in this experiment. Each animal was admin-
istered 30 mg}kg of trazodone, calculated as free base, by
intraperitoneal (i.p.) injection. Previous studies (Miller and
DeVane, 1986) suggested that a dose of 30 mg}kg in rats
would produce plasma concentrations similar to that seen
in man following single oral dose administration of 50 mg
(Abernethy et al., 1984).
The time-course of trazodone and m-CPP concen-
trations in rat plasma and brain tissue from administration
of trazodone was determined at eight timed intervals
following drug administration : 0±5, 1, 1±5, 2, 3, 4, 5 and
6 h. Five animals were sacrificed at each time-point. After
ether anaesthesia, blood was obtained by cardiac puncture
for collection of plasma. The animals were then im-
mediately decapitated and their brains rapidly excised.
The brains were weighed and stored at ®20 °C for
subsequent analysis by high performance liquid chroma-
tography (HPLC) as described below. Additional animals
not treated with trazodone were sacrificed and processed
in the same manner in order to obtain drug-free plasma
and tissues for preparation of HPLC calibration curves.
Chronic administration
Six groups of animals, consisting of 6–8 animals per
group, had osmotic mini-pumps (Alzet2 Osmotic Pump,
model 2ML1, Alza Corp., Palo Alto, CA) containing
trazodone implanted into their peritoneal cavity by a
procedure which has been previously described (DeVane
and Laizure, 1986). Four groups of male rats weighing
approximately the same as those in the single-dose
experiment were used to assess trazodone and m-CPP
concentrations in plasma and brain following continuous
dosing ; with each of the four groups receiving either 5,
10, 30 or 50 mg}kg per day trazodone (calculated as
base). Two additional groups of female animals were also
studied. Their pumps contained trazodone calculated to
deliver a dose of 30 mg}kg per day. One group was not
pregnant while the other group consisted of pregnant
animals whose pregnancies were accurately timed by the
observation of sperm in the vaginal lumen (day of
insemination¯ day 0). All surgery for mini-pump implan-
tation was performed on the same day. For the pregnant
animals, this corresponded to day 15 or day 16 of their
expected 21 d gestation period.
After the animals had recovered from surgery and had
been treated for 4 d, a period of time estimated to exceed
that required to achieve steady-state conditions, they
were sacrificed in a manner similar to that described above
for the single-dose experiment. The day of sacrifice
corresponded to days 19 or 20 of gestation for the
pregnant animals. As the animals were expected to gain
weight during the period following surgery, they were
weighed again immediately prior to sacrifice to calculate
the final daily trazodone dose. Additional tissues were
saved from pregnant animals for HPLC analysis : whole
fetuses ; fetal livers ; fetal brains, and placental tissue. Each
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tissue was immediately weighed, stored on dry ice, then
frozen for subsequent analysis by HPLC. The procedure
for tissue collection from pregnant animals has been
previously described (DeVane and Simpkins, 1985).
Assay procedure
The validated HPLC method of Miller and DeVane (1986)
was used for all analyses. Samples were analysed on the
same day as collection. Brain, plasma and fetal tissue
samples were prepared and extracted as previously
described. Briefly, tissue samples were homogenized, each
sample was then alkalinized with saturated sodium borate
solution and extracted with methyl-tert-butyl ether.
Samples were then back-extracted with phosphoric acid
and an aliquot of the aqueous phase injected onto a
reversed-phase C
"
column. A mobile phase of acetonitrile
and phosphate buffer, pH 3±0, was used to elute the
compounds of interest. Quantitation was performed by
comparing peak height ratios of trazodone or m-CPP to
an internal standard (200 ng bupropion hydrochloride)
with ratios derived from a calibration curve of standards
containing known amounts of drug and metabolite
extracted from plasma or tissue as described above. An
IBM chromatograph was used with detection by UV
absorbance monitoring at 214 nm. Final concentrations of
trazodone and m-CPP were expressed as either ng}ml for
plasma or ng}g for brain and fetal tissues. The limit of
detection was 1±0 ng}ml for both trazodone and m-CPP.
The intra-day coefficient of variation (CV) for trazodone
and m-CPP extracted from plasma and tissues was ! 2±1
and ! 7±0%, respectively.
Data analysis
Pharmacokinetic parameters were determined by inspec-
tion of the empirical data. Half-lives were determined by
least squares linear regression analysis of the log-
transformed data points of the terminal slope from the
single-dose experiment. Area under the curve (AUC)
calculations were made using the trapezoidal rule.
For the continuous dosing experiment, a linear re-
gression analysis was used to examine correlations
between administered dose and the resulting plasma
trazodone and m-CPP concentrations. Additional corre-
lations were sought between trazodone plasma con-
centration as the independent variable and brain tissue
trazodone and m-CPP concentrations as dependent vari-
ables. A one-way analysis of variance was used to test for
differences in means of steady-state plasma concen-
trations, normalized for dose, between males, females and
pregnant females. The level of significance was set at p¯
0±05. All data are quoted as mean³.. unless otherwise
stated.
Results
Plasma and brain tissue concentrations of trazodone and
m-CPP vs. time profile for the single-dose experiment are
shown in Figure 1. Concentrations in plasma and brain
were comparable to similar single oral doses of trazodone
(Caccia et al., 1981b ; Cervo et al., 1981). In our
experiment, trazodone was rapidly absorbed and distri-
buted extensively into brain tissue. In the first timed
sample, at 0±5 h, concentrations of trazodone were at their
maximum in all tissues examined. The ratio of trazodone
concentration in brain tissue to that in plasma in the first
sample was 6±0. Brain tissue m-CPP concentration ex-
ceeded plasma m-CPP concentration by a factor of 53.
Except for the first sample, brain tissue concentrations of
m-CPP always exceeded those of trazodone in the
subsequent samples over the 6 h of the study. The
single-dosepharmacokinetic parameters are summarized in
Table 1.
Animals sacrificed after 4 d of continuous trazodone
dosing were found to have lower concentrations of
trazodone in brain tissue compared to those found in
plasma, a situation in contrast to the single-dosing
situation (Figure 1). For all chronically dosed animals with
measurable concentrations of trazodone, the ratio of brain
to plasma trazodone concentration was 0±53³0±17 (n¯
35), the mean dose of trazodone was 20±0³13±5 mg}kg.
In further contrast to the single-dose situation, brain tissue
trazodone concentrations were higher than m-CPP con-
Figure 1. Concentration vs. time profile for m-CPP (circles)
and trazodone (squares) in plasma (open symbols) and brain
tissue (closed symbols) of male rats following a single
intraperitoneal trazodone dose of 30 mg}kg. Each point
represents the mean (³...) of 4 or 5 animals. ...s not
shown were smaller than the symbol size.
20 C. L. DeVane et al.
Table 1. Pharmacokinetic parameters for trazodone and m-CPP in rat plasma and brain following a single dose of 30 mg}kg of































Plasma 0±5 881 (209) 1±79 734 0±5 86 (17) 1±03 94
Brain 0±5 5262 (1043) 1±21 4419 0±5 4542 (964) 1±16 5376
*Data is mean (³...), n¯ 4 or 5.
Figure 2. Mean (³...) steady-state concentrations of
trazodone and m-CPP in chronically dosed rats.
Figure 3. Relationship in rats continuously dosed with trazodone between (a) dose and brain trazodone concentration (n¯ 42)
and (b) plasma and brain trazodone concentrations (n¯ 34). Lines represent the linear regression lines of best fit.
centrations in all animals. The ratio of brain tissue
trazodone concentration to brain tissue m-CPP con-
centration was 3±49³2±50 (n¯ 40). In most animals,
m-CPP was present in only trace amounts in plasma
(! 5 ng}ml), while it was measurable in the brain tissue
of all animals. Figure 2 shows the steady-state concen-
trations of trazodone and m-CPP in plasma and brain
tissue for the continuous dose study.
The relationship between administered dose and result-
ing trazodone plasma concentration was significant but
considerable variability was observed (r¯ 0±68,
p! 0±0001). Other correlations between dose and re-
sulting concentration of either drug or metabolite in
plasma or brain were similar (range : r¯ 0±64–0±76).
Using plasma trazodone concentration as the independent
variable, a strong linear relationship existed with brain
tissue trazodone concentration (r¯ 0±96, p! 0±0001).
This relationship is shown in Figure 3 and is compared
with the relationship between trazodone dose and its
brain tissue concentration. No simple relationship was
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Figure 4. Mean (³...) steady-state concentrations of
trazodone in maternal plasma and tissues of pregnant rats and
fetuses (n¯ 5).
observed between the concentration of m-CPP in plasma
and that in brain (r¯ 0±37).
Because of differences in the final weight of chronically
dosed animals at sacrifice compared to baseline before
pump implantation, animals could not be strictly assigned
to the original dose groups. Therefore, comparison of
mean steady-state concentrations between males, females,
and pregnant females was made by normalizing each
animal’s plasma concentration by their final mg}kg dose.
No significant difference in mean steady-state plasma
concentration for administered dose was found between
males (mean³..., 17±6³8±6 ng}ml per mg}kg, n¯
26) and females (26±1³5±65 ng}ml per mg}kg, n¯ 5) or
between females and pregnant females (32±4³
14±1 ng}ml per mg}kg, n¯ 5).
Assay of fetal tissues for trazodone and m-CPP found
measurable trazodone concentrations in all tissues ex-
amined. These results are shown in Figure 4. The order of
concentrations from highest to lowest for trazodone was
maternal plasma" placenta" fetal liver" fetal brain
"whole fetus¯maternal brain. m-CPP was present in
relatively low concentration in the fetal tissues examined
(! 25 ng}g of tissue).
Discussion
Experience with the tricyclic antidepressants and fluoxe-
tine has shown that metabolites may be important in
producing therapeutic and}or toxic response. m-CPP
appeared rapidly in plasma following a single dose of
trazodone (Figure 1). As the intraperitoneal route of
administration is analogous to oral administration in
humans, these results suggest that m-CPP is formed by
pre-systemic elimination (first-pass effect) in the liver and
gut wall. In addition, m-CPP concentration was higher in
brain tissue than plasma in both the single- and con-
tinuous-dose experiments. Measurable amounts of m-CPP
in human plasma have been reported after single oral
trazodone doses (Fong et al., 1982b ; Ishida et al., 1995 ;
Lawlor et al., 1997). Thus, brain concentrations of m-CPP
formed from administered trazodone may reach thera-
peutically effective levels.
Of interest in our study was the paradoxically higher
concentrations in the brain of m-CPP compared to
trazodone following a single dose. This contrasts with
lower concentrations of m-CPP than trazodone in plasma
(Figure 1). m-CPP may be less tightly bound to plasma
proteins than trazodone, thus allowing a greater amount
of free drug to reach the site of action. m-CPP may bind
more avidly to central nervous system tissue than
trazodone. Plasma protein or tissue-binding studies of
m-CPP have not yet been reported. An influx pump with
different affinities for trazodone and m-CPP, which is
down-regulated at steady-state, or changes in brain
metabolism at steady-state, may also account for apparent
high initial blood–brain barrier permeability.
This study found major differences in relative drug and
metabolite concentrations in brain tissue following con-
tinuous dosing compared to the single-dose situation.
While m-CPP concentrations were generally greater than
trazodone in brain tissue following a single dose (Figure
1), at steady-state trazodone predominated over m-CPP
in the brain (Figure 2). This was an unexpected finding
that would not be predicted from the single-dose data. It
is possible that during the accumulation to steady-state
that the overall clearance of formed m-CPP changes and a
greater proportion of the metabolite is eliminated over
time. Alternatively, the clearance of trazodone might
decline at steady-state. Rurak and Melzacka (1983)
previously reported that trazodone concentration in the
rat brain was lower after chronic dosing than from single-
dose administration. Friedman and Cooper (1983) found
evidence for altered disposition of desmethylclomipra-
mine in rats when clomipramine was given repeatedly
compared to a single dose.
The relevance of these observations for neuropharma-
cological studies is the suggestion that pharmacologic
actions of antidepressants, especially those with active
metabolites, may differ according to the route and time-
course of administration. Other factors in experimental
design of neuropharmacological studies are important.
Aulakh et al. (1988) found that the neuroendocrine
responses to the administration of m-CPP differed
according to the strain of rat used experimentally. While
we did not find significant differences between the mean
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trazodone concentration in brains of male compared to
female animals, therewas a trend for higher concentrations
per administered dose in the females.
We found a strong linear relationship existed between
dose and the resulting trazodone brain concentration
(Figure 3). Not surprisingly, a stronger correlation existed
with plasma concentration and brain concentration. This
probably reflects an equilibrium between the drug in the
plasma and drug in the brain suggesting that a true
steady-state existed due to the use of mini-osmotic
pumps. These pumps are rate-controlled drug-delivery
systems for implantation in laboratory animals. A major
advantage of their use is that a constant-rate of drug input
can be achieved, similar to a constant rate intravenous
infusion. This avoids the necessity of daily drug dosing.
Other advantages are simplicity of animal preparation and
minimal animal stress following recovery from surgery.
They have been used successfully in previous studies of
neuroreceptor sensitivity changes and endocrine effects
from chronic antidepressant therapy (Wozniak et al.,
1989a,b) ; however, we cannot exclude the possibility that
this method of drug administration influenced the kinetics
of trazodone and m-CPP.
By analysing tissues for trazodone and m-CPP concen-
trations in pregnant animals, this study found that
trazodone crossed the placenta and was distributed into
the fetus of rats. However, the steady-state concentrations
of trazodone were much lower in fetal tissue than in the
maternal plasma. Only trace amounts of m-CPP were
present in the fetus compared to trazodone. This finding
contrasts with the results of experiments using other lipid
soluble antidepressants. We previously found that imi-
pramine, and its metabolite desipramine, were extensively
distributed to rat fetal tissue from maternal plasma
(DeVane and Simpkins, 1985). However, the apparent
lesser degree of trazodone’s transplacental distribution
does not imply a greater safety of trazodone in pregnancy
compared with imipramine. Drug effects on the fetus are
determined by a number of factors, including the duration
of drug exposure, gestational age of the fetus, and
inherent pharmacological properties of the drug. These
results demonstrate that trazodone, like other anti-
depressants, is capable of reaching the fetus following
maternal drug administration (Calabrese et al., 1985).
In summary, these studies found that intraperitoneally
administered trazodone to rats resulted in rapid ap-
pearance of trazodone and its major metabolite, m-CPP, in
both plasma and brain tissue. While m-CPP was the
predominant compound in the brain following a single
dose, this finding did not hold for continuous dosing. This
implies that trazodone’s kinetic parameter may change
with chronic administration. If replicated, this means that
the results of single-dose studies in animals may not be
appropriate to extrapolate to the situation in man where
antidepressants are usually administered continuously for
several weeks or months. A linear relationship was
apparent between plasma and brain concentrations of
trazodone but no simple relationship was found for the
metabolite. For trazodone, the results of the continuous
administration experiments are likely to be of most
experimental and clinical relevance. These findings sug-
gest that future studies should carefully examine ex-
perimental strategies including acute vs. chronic kinetics
and the relationships between drug and active metabolites
that may account for pharmacologic effects.
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